Bessemer Group Inc. boosted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 154.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,568,148 shares of the healthcare product maker's stock after purchasing an additional 1,557,146 shares during the period. Bessemer Group Inc. owned approximately 0.15% of Abbott Laboratories worth $253,811,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. lifted its holdings in shares of Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after buying an additional 6,769,518 shares during the period. State Street Corp grew its holdings in Abbott Laboratories by 1.7% during the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker's stock worth $7,343,246,000 after acquiring an additional 1,350,766 shares during the period. Bank of America Corp DE acquired a new position in Abbott Laboratories during the second quarter worth about $1,603,607,000. Deutsche Bank AG raised its position in Abbott Laboratories by 18.6% in the second quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker's stock worth $1,515,963,000 after acquiring an additional 2,614,965 shares in the last quarter. Finally, Legal & General Group Plc bought a new stake in Abbott Laboratories in the second quarter worth about $1,082,524,000. 75.18% of the stock is owned by institutional investors.
Abbott Laboratories Price Performance
Shares of ABT opened at $108.59 on Monday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.00 and a current ratio of 1.45. The firm has a market cap of $188.08 billion, a PE ratio of 40.52, a PEG ratio of 1.90 and a beta of 0.54. The firm's 50 day moving average price is $103.93 and its 200 day moving average price is $101.74. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $132.02.
Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting the consensus estimate of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The company had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. During the same period in the previous year, the firm posted $1.30 earnings per share. The company's revenue for the quarter was up 14.5% compared to the same quarter last year. As a group, research analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.
Abbott Laboratories Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories's dividend payout ratio is presently 94.03%.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on ABT. BTIG Research cut their price target on shares of Abbott Laboratories from $134.00 to $125.00 and set a "buy" rating for the company in a report on Thursday, October 22nd. Citigroup dropped their price target on Abbott Laboratories from $125.00 to $122.00 and set a "buy" rating on the stock in a report on Thursday, October 22nd. Royal Bank Of Canada cut their price objective on Abbott Laboratories from $130.00 to $125.00 and set an "outperform" rating for the company in a research report on Thursday, October 22nd. TD Cowen reduced their price objective on Abbott Laboratories from $135.00 to $118.00 and set a "buy" rating for the company in a research note on Thursday, October 22nd. Finally, Wall Street Zen raised Abbott Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, October 24th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $118.32.
Check Out Our Latest Research Report on Abbott Laboratories
Insiders Place Their Bets
In other Abbott Laboratories news, EVP Mary Moreland sold 3,500 shares of the firm's stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $116.00, for a total transaction of $406,000.00. Following the transaction, the executive vice president directly owned 100,791 shares in the company, valued at $11,691,756. This trade represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is currently owned by company insiders.
Abbott Laboratories Company Profile
(
Free Report)
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott's offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Read More
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.